Pharma firms’ focus on weight-loss drugs could put insulin supply at risk, experts warn

November 10, 2026 · 1:00 pm 3 sources

Image: The Guardian

Coverage

Wires & papers of record

• Pharma firms’ focus on weight-loss drugs could put insulin supply at risk, experts warn
  The Guardian · November 10, 2026 13:00
  GLP-1 products such as Ozempic and Mounjaro spread but many in poorer countries struggle to get basic diabetes treatment The gold rush into GLP-1 weight-loss drugs risks diverting pharmaceutical firms’ attention away from diabetes treatments such as insulin, the head of the Access to Medicine…
• Makers of GLP-1 drugs ordered to add warnings about rare eye condition that can lead to blindness
  BBC News · November 10, 2026 18:43
  The US Food and Drug Administration says Ozempic, Wegovy, and other weight-loss drugs must have labels about the condition, known as NAION.
• FDA warns of rare eye condition causing blindness from GLP-1 weight loss medications
  The Guardian · November 10, 2026 20:18
  The federal agency is requiring all GLP-1s to include information about the potential risk on warning labels The US Food and Drug Administration (FDA) has issued a new warning on GLP-1 medications – which can facilitate weight loss – over a rare eye condition that could lead to sudden and…